Stocks in news: BSE, HAL, Asian Paints, Tata Steel, Tata Power

The markets witnessed a volatile session on the weekly expiration day but ultimately ended in the green, extending Monday’s recovery. Technically, analysts say the Nifty has regained its short-term moving average, the 20-DEMA, around 25,600. Staying above this level could open the door for a move towards 25,800-26,000, while any weakness below could lead to profit taking.“Continued resilience in major banks, along with strength in IT stocks, provides comfort for a potential recovery. Traders are advised to maintain a stock-specific approach, emphasizing risk management and rotation opportunities across sectors, amid the prevailing volatility,” said Ajit Mishra – SVP, Research, Religare Broking.

In today’s trading, stocks of BSE, HAL, Asian Paints, Tata Steel and Tata Power, among others, will be in focus following various news developments and Q2 results.BSE

BSE reported 61% growth in consolidated net profit in the second quarter at Rs 558 crore, compared to Rs 347 crore in the same period a year ago. The profit after tax (PAT) is attributable to the shareholders of the company. The company’s revenue in the quarter ended September was Rs 1,068 crore, up 44% from Rs 741 crore in the corresponding quarter of the last fiscal.

AWL Agribusiness
Fair trade regulator CCI approved Wilmar International’s proposal to acquire up to 20 percent stake in AWL Agri Business Ltd from Adani Group. The move came after Adani Group announced in July this year that it will sell 20 percent stake in AWL Agri Business (formerly Adani Wilmar Ltd) to Singapore-based Wilmar International for Rs 7,150 crore, as part of its decision to exit the FMCG business and focus on its vertical infrastructure.

Cipla
Indian pharmaceutical companies operating in China have made some progress in the Chinese market by winning bids for the supply of bulk generic drugs, especially the widely prescribed Dapagliflozin, which is used to treat diabetes. Indian companies, Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma, have won the Chinese Health Ministry’s bids to procure pharmaceutical products for its hospitals, according to the India-China Economic and Cultural Council (ICEC).Tata power
Tata Power plans to set up the country’s largest solar wafer and block manufacturing plant with a capacity of 10 gigawatts, CEO Praveer Sinha said. The factory where the blocks and wafers – the basic material for solar cells – are made would complete Tata Power’s presence in the product’s production chain. The company already has 4.9 GW of integrated capacity for making cells and modules.

Torrent pharma
Ahmedabad-based Torrent Pharma, the flagship of the Torrent Group, is charting an ambitious growth path by focusing on innovation in chronic therapies and expanding into high-growth segments. The company, known for its Rs 500-crore vitamin brand Shelcal (including variants) and Rs 245-crore heart drug Nikoran, plans to leverage its core strengths while venturing into emerging areas such as weight loss therapies, TOI reported.

Zydus
Zydus Lifesciences said it has received approval from China’s health regulator to market a drug for the treatment of depressive disorders, among other things. The company has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine extended release capsules in strengths of 75 mg and 150 mg respectively, the drug company said in a statement.

RVNL
State-owned RVNL on Tuesday reported a decline in consolidated net profit by around 20% to Rs 230.52 crore in the September quarter, impacted by higher costs. The company had posted a net profit of Rs 286.90 crore in the year-ago period, the company said in a stock exchange filing. The company’s total revenue rose to Rs 5,333.36 crore from Rs 5,136.07 crore in July-September FY25.

HAL, Asian paint, Tata Steel, Ashok Leyland, Info Edge
Shares of HAL, Asian Paints, Tata Steel, Ashok Leyland and Info Edge will be in focus as the companies announce their second quarter results today.

Bharat forge
Bharat Forge said its board has approved to raise up to Rs 2,000 crore through various instruments including term loans, non-convertible debentures or other debt instruments. The board has granted in-principle approval for raising funds not exceeding the core value of Rs 20.00 through term loans, non-convertible debentures or other debt instruments and has delegated powers to the investment committee – strategic matters in this regard, the Pune-based company said.